Sanofi-Aventis Natterman & Cie.GmbH, Germany
| Държава: | Германия |
| Кратка информация: | Growth Platforms Pharmaceuticals Human Vaccines Animal Health Geographic Presence Sanofi is a diversified global healthcare company engaged in the research, development, manufacture and marketing of healthcare products. Our business includes pharmaceuticals, comprising prescription drugs, consumer healthcare and generics; vaccines and animal health. 2010 net sales: €30,384 million, +3.7% on a reported basis, -0.8% at constant exchange rates (CER) versus 2009 H1 2011 sales: €16,128 million, -0.5% on a reported basis, +1.0% at constant exchange rates (CER) versus H1 2010 2010 business EPS: €7.06, +6.8% on a reported basis, +2.6% at CER versus 2009 H1 2011 business EPS: €3.30, -12.2% on a reported basis, -11.7% at CER versus H1 2010 Growth Platforms Sanofi has identified key growth platforms: Emerging Markets (World excluding U.S., Canada, Western Europe, Japan, Australia and New Zealand), Human Vaccines, Consumer Health Care, Diabetes Solutions, New Products and Animal Health (animal health sales were not consolidated in 2010 and therefore not reflected in percentages representing our growth platforms in 2010). In April 2011, Sanofi realized the acquisition of Genzyme, a leading biotechnology company. 2010 consolidated net sales of growth platforms: €16,424 million, +12.5% at CER 54% of total consolidated sales compared with 47% for 2009 2010 Animal Health sales (not consolidated): €1,983 million, +2.6% at CER H1 2011 sales (incl. Animal Health, consolidated since Q1 2011): €9,258 million, +7.0% at CER Including Genzyme, growth platforms represented 62.3% of total sales Growth platformsMillions of euros 2010 net sales Change at CER Emerging Markets* 9,075 +16.3% Emerging Markets excluding Diabetes, Vaccines, CHC and new products 5,847 +6.6% Diabetes 4,298 +9.2% Vaccines 3,808 +4.8% Consumer Health Care 2,217 +45.7% New Products 254 - Total Growth Platforms 16,424 +12.5% * including Diabetes, Vaccines and Consumer Health Care sales generated in Emerging Markets Pharmaceuticals 2010 net sales of the pharmaceuticals business: €26,576 million, -1.6% at CER H1 2011 sales: €13,730 million, +3.3% at CER Sanofi's pharmaceuticals business notably focuses on diabetes, oncology, and other flagship products in thrombosis and cardiovascular areas. Our flagship products in 2010 were: Lantus®, Apidra® and Amaryl® in diabetes; Taxotere®, Eloxatin® and Jevtana® in oncology; as well as Lovenox®, Plavix®, Aprovel® and Multaq® in thrombosis and cardiovascular diseases. Sanofi also has a significant presence in Consumer Health Care, in various product categories. 2010 net sales of Consumer Health Care: €2,217 million, +45.7% at CER H1 2011 sales: €1,356 million, +28.1% at CER In addition, our pharmaceuticals portfolio comprises other prescription drugs including Generics. 2010 net sales of Generics: €1,534 million, +41.5% at CER H1 2011 sales: €848 million, +17.3% at CER Further details on net sales Top of page Human Vaccines Sanofi Pasteur, the fully integrated vaccines business of Sanofi, is a world leader in the vaccines industry offering a large range of vaccines covering 20 different infectious diseases. 2010 net sales of the vaccines business: €3,808 million, +4.8% at CER H1 2011 sales: €1,308 million, +6.0% at CER, excl. A/H1N1 influenza vaccine sales booked in H1 2010 (-20.3% at CER, incl. A/H1N1 influenza vaccines sales) Non-consolidated 2010 sales of Sanofi Pasteur MSD (50/50 joint-venture with Merck): €918 million, -18.9% on a reported basis H1 2011 sales of Sanofi Pasteur MSD: €308 million, -14.9% on a reported basis Further details on net sales Top of page Animal Health Merial, a wholly owned subsidiary of Sanofi since September 18, 2009, is one of the world’s leading animal health companies dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines used by veterinarians, farmers and pet owners. Non-consolidated 2010 sales of Merial: €1,983 million, +2.6% at CER Consolidated H1 2011 sales: €1,090 million, +6.7% at CER Merial sales are consolidated since Q1 2011. Further details on net sales Top of page Geographic Presence Sanofi has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. Sanofi is the established leader in Emerging Markets, holding top positions in the main countries. In 2010, Emerging Markets generated €9,075 million of sales, accounting for 29.9% of total sales and thus the largest contributor to Group sales by region. In H1 2011, Emerging Markets sales were €4,919 million, +10.5% excluding Genzyme and A/H1N1 vaccines (+2.2% excluding Genzyme). |
| Сайт: | http://www.sanofi.com/ |
Търсене в сайта
Лекарствен справочник
http://sommons.co/out?zoneId=2647810-2647961 Банер II
